The dawn of a new era of targeted lipid-lowering therapies

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial

(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · see citing works

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · see citing works

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works

Atherosclerosis

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211 · see citing works

Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease

Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · see citing works

Effects of torcetrapib in patients at high risk for coronary events

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · see citing works

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985 · see citing works

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · see citing works

Untitled work

(1999) · PubMed · Cited by 2,062 · see citing works

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · see citing works

Interpretation of the evidence for the efficacy and safety of statin therapy

Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · see citing works

Effects of extended-release niacin with laropiprant in high-risk patients

The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601 · see citing works

Triglycerides and cardiovascular disease

Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · see citing works

HDL cholesterol efflux capacity and incident cardiovascular events

Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · see citing works

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · see citing works

Overcoming cellular barriers for RNA therapeutics

Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · see citing works

Effects of anacetrapib in patients with atherosclerotic vascular disease

The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047 · see citing works

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028 · see citing works

Genetic Associations with Valvular Calcification and Aortic Stenosis

Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008 · see citing works

Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · see citing works

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979 · see citing works

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · see citing works

EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa047 · Cited by 839 · see citing works

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · see citing works

Evacetrapib and cardiovascular outcomes in high-risk vascular disease

Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · see citing works

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03534-y · Cited by 793 · see citing works

Variation in<i>PCSK9</i>and<i>HMGCR</i>and Risk of Cardiovascular Disease and Diabetes

Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743 · see citing works

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61730-x · Cited by 704 · see citing works

Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus

The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698 · see citing works

HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms

Navab, M., Reddy, S. T., Lenten, B. J. V., & Fogelman, A. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.222 · Cited by 656 · see citing works

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals

Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632 · see citing works

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 574 · see citing works

Clinical review on triglycerides

Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544 · see citing works

Lipid-Related Markers and Cardiovascular Disease Prediction

The Emerging Risk Factors Collaboration (2012) · JAMA · doi:10.1001/jama.2012.6571 · Cited by 539 · see citing works

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes‐Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 499 · see citing works

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498 · see citing works

Cognitive function in a randomized trial of evolocumab

Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492 · see citing works

ANGPTL3 deficiency and protection against coronary artery disease

Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467 · see citing works

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432 · see citing works

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407 · see citing works

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · see citing works

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

Johannesen, C. D. L., Mortensen, M. B., Langsted, A., & Nordestgaard, B. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.027 · Cited by 359 · see citing works

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864671 · Cited by 358 · see citing works

The metabolism and anti-atherogenic properties of HDL

Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331 · see citing works

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works

Evinacumab in Patients with Refractory Hypercholesterolemia

Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302 · see citing works

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279 · see citing works

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

Wood, F. A., Howard, J. P., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031173 · Cited by 274 · see citing works

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

Enkhmaa, B., Anuurad, E., & Berglund, L. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r051904 · Cited by 261 · see citing works

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · see citing works

Triglycerides and residual atherosclerotic risk

Raposeiras-Roubin, S., Rosselló, X., Oliva, B., Fernández-Friera, L., Mendiguren, J. M., Andrés, V., Bueno, H., Sanz, J., Martínez de Vega, V., Abu-Assi, E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.059 · Cited by 254 · see citing works

High-density lipoproteins, reverse cholesterol transport and atherogenesis

Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00538-z · Cited by 250 · see citing works

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

Lepist, E., Zhang, X., Jia, H., Huang, J., Kosaka, A. H., Birkuš, G., Murray, B. P., Bannister, R. M., Cihlář, T., Huang, Y. L., et al. (2014) · Kidney International · doi:10.1038/ki.2014.66 · Cited by 242 · see citing works

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Pinkosky, S. L., Filippov, S. I., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 240 · see citing works

Causes and consequences of hypertriglyceridemia

Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239 · see citing works

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(21)00046-2 · Cited by 232 · see citing works

N-acetyl galactosamine-conjugated antisense drug to <i>APOC3</i> mRNA, triglycerides and atherogenic lipoprotein levels

Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231 · see citing works

The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction

Orringer, C. E., Blaha, M. J., Blankstein, R., Budoff, M. J., Goldberg, R. B., Gill, E. A., Maki, K. C., Mehta, L. S., & Jacobson, T. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.005 · Cited by 231 · see citing works

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

Gudbjartsson, D. F., Þorgeirsson, G., Sulem, P., Helgadóttir, A., Gylfason, A., Saemundsdottir, J., Björnsson, E., Norddahl, G. L., Jónasdóttir, Á., Jónasdóttir, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.019 · Cited by 227 · see citing works

Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease

Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198 · see citing works

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

Banach, M., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Flaim, J., Ye, Z., & Catapano, A. L. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2314 · Cited by 191 · see citing works

A<i>PCSK9</i>Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction

Kathiresan, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707445 · Cited by 183 · see citing works

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry

Klempfner, R., Erez, A., Sagit, B.-Z., Goldenberg, I., Fisman, E., Kopel, E., Shlomo, N., Israel, A., & Tenenbaum, A. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002104 · Cited by 180 · see citing works

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.050 · Cited by 175 · see citing works

Lipid-Lowering Agents: Targets Beyond PCSK9

Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171 · see citing works

Surprises from genetic analyses of lipid risk factors for atherosclerosis

Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159 · see citing works

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation · doi:10.1161/circulationaha.118.034710 · Cited by 154 · see citing works

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 148 · see citing works

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136 · see citing works

Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants

Grosskopf, I., Baroukh, N., Lee, S., Kamari, Y., Harats, D., Rubin, E. M., Pennacchio, L. A., & Cooper, A. D. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000186189.26141.12 · Cited by 128 · see citing works

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation · doi:10.1161/circulationaha.116.024604 · Cited by 127 · see citing works

EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study

So, J., Wu, D., Lichtenstein, A. H., Tai, A. K., Matthan, N. R., Maddipati, K. R., & Lamon-Fava, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.018 · Cited by 127 · see citing works

Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population

Hansen, S. E. J., Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.294926 · Cited by 121 · see citing works

From High-Density Lipoprotein Cholesterol to Measurements of Function

Sacks, F. M., & Jensen, M. K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.307025 · Cited by 119 · see citing works

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)

Stiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa171 · Cited by 119 · see citing works

Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease

Duran, E. K., & Pradhan, A. D. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa296 · Cited by 108 · see citing works

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Bloedon, L. T., et al. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.08.009 · Cited by 103 · see citing works

From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases

Landmesser, U., Poller, W. C., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 100 · see citing works

Reversal of siRNA-mediated gene silencing in vivo

Zlatev, I., Castoreno, A. B., Brown, C. R., Qin, J., Waldron, S., Schlegel, M. K., Degaonkar, R., Shulga‐Morskaya, S., Xu, H., Gupta, S., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4136 · Cited by 96 · see citing works

Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial

Rubino, J., MacDougall, D. E., Sterling, L. R., Hanselman, J. C., & Nicholls, S. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.023 · Cited by 94 · see citing works

The Endothelium Is Both a Target and a Barrier of HDL’s Protective Functions

Robert, J., Osto, E., & von Eckardstein, A. (2021) · Cells · doi:10.3390/cells10051041 · Cited by 88 · see citing works

Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis

Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313864 · Cited by 87 · see citing works

Novel Insights From Human Studies on the Role of High-Density Lipoprotein in Mortality and Noncardiovascular Disease

Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314050 · Cited by 87 · see citing works

Triglycerides on the rise: should we swap seats on the seesaw?

Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85 · see citing works

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

Gibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., Nicholls, S. J., Pocock, S., Goodman, S. G., Alexander, J. H., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.052 · Cited by 84 · see citing works

Loss- and Gain-of-function PCSK9 Variants

Benjannet, S., Hamelin, J., Chrétien, M., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399725 · Cited by 83 · see citing works

Mendelian randomization studies

Ference, B. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000247 · Cited by 83 · see citing works

HDL-cholesterol and cardiovascular disease: rethinking our approach

Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77 · see citing works

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial

Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1157 · Cited by 76 · see citing works

Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans

Mendivil, C. O., Furtado, J. D., Morton, A. M., Wang, L., & Sacks, F. M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306138 · Cited by 74 · see citing works

Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study

Balling, M., Nordestgaard, B. G., Langsted, A., Varbo, A., Kamstrup, P. R., & Afzal, S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.072 · Cited by 73 · see citing works

EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol

Jacobs, M. L., Faizi, H. A., Peruzzi, J. A., Vlahovska, P. M., & Kamat, N. P. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.04.009 · Cited by 72 · see citing works

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Rubino, J., MacDougall, D. E., Sterling, L. R., Kelly, S. E., McKenney, J. M., & Lalwani, N. D. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.05.002 · Cited by 69 · see citing works

Polygenic determinants in extremes of high-density lipoprotein cholesterol

Dron, J. S., Wang, J., Low‐Kam, C., Khetarpal, S. A., Robinson, J. F., McIntyre, A. D., Ban, M. R., Cao, H., Rhainds, D., Dubé, M., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m079822 · Cited by 63 · see citing works

Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries

Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 62 · see citing works

Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Wang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01101-9 · Cited by 60 · see citing works

Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study

Thomas, D. G., Wei, Y., & Tall, A. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p120001000 · Cited by 52 · see citing works

Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography

Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz329 · Cited by 42 · see citing works

The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis

Verberk, S. G. S., Kuiper, K. L., Lauterbach, M. A. R., Latz, E., & den Bossche, J. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.09.004 · Cited by 36 · see citing works

Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

Masson, W. M., Lobo, M., Siniawski, D. A., Molinero, G. B., Masson, G., Huerin, M. S., & Nogueira, J. P. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01297-5 · Cited by 30 · see citing works

Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen

Karwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.036 · Cited by 27 · see citing works

In-depth Mendelian randomization analysis of causal factors for coronary artery disease

Tan, Y.-D., Xiao, P., & Guda, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-66027-4 · Cited by 17 · see citing works

4-LB: Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES

Bhatt, D. L., Brinton, E. A., Miller, M. J., Steg, P. G., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C. B., et al. (2020) · Diabetes · doi:10.2337/db20-4-lb · Cited by 16 · see citing works

Targeting RNA to lower triglycerides: long strides from short molecules

Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14 · see citing works

Lipoprotein (a)

Libby, P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.08.007 · Cited by 13 · see citing works

Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

Fruchart, J., Santos, R. D., Yamashita, S., Libby, P., Fruchart, J., Santos, R. D., Yamashita, S., Aikawa, M., Libby, P., Plutzky, J., et al. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.034 · Cited by 6 · see citing works

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

Lobo, L., Molinero, G. B., Masson, W. M., Siniawski, D. A., Masson, G., Huerin, M. S., Nogueira, J. P., Benincasa, F., Losada, P., & Suárez, F. (2020) · European Heart Journal · doi:10.1093/ehjci/ehaa946.2981 · Cited by 3 · see citing works

2024 ESC Guidelines for the management of chronic coronary syndromes

Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,314 · see citing works

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., & Nissen, S. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00215-5 · Cited by 694 · see citing works

Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women

Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I.-M. M., & Buring, J. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405182 · Cited by 300 · see citing works

Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease

Nelson, K. A., Fuster, V., & Ridker, P. M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.055 · Cited by 204 · see citing works

Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies

Du, Z., & Qin, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010363 · Cited by 140 · see citing works

Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial

Yu, M., Yang, Y., Dong, S., Zhao, C., Yang, F., Yuan, Y.-F., Liao, Y.-H., He, S.-L., Liu, K., Wei, F., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069808 · Cited by 119 · see citing works

Overview and New Insights into the Metabolic Syndrome: Risk Factors and Emerging Variables in the Development of Type 2 Diabetes and Cerebrocardiovascular Disease

Hayden, M. R. (2023) · Medicina · doi:10.3390/medicina59030561 · Cited by 123 · see citing works

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works

Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review

Rouland, A., Masson, D., Lagrost, L., Vergès, B. L., Gautier, T., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01703-5 · Cited by 103 · see citing works

High lipoprotein(a): Actionable strategies for risk assessment and mitigation

Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 83 · see citing works

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 79 · see citing works

Structural Elucidation and Activities of Cordyceps militaris-Derived Polysaccharides: A Review

Miao, M., Yu, W., Li, Y., Sun, Y., & Guo, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.898674 · Cited by 73 · see citing works

Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events

Markus, M. R. P., Ittermann, T., Mariño, J., Schipf, S., Bahls, M., Könemann, S., Chamling, B., Völzke, H., Damasceno, N. R. T., Santos, R. D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf281 · Cited by 58 · see citing works

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57 · see citing works

APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia

Prohaska, T. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Tami, J. A., Xia, S., Witztum, J. L., & Tsimikas, S. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.04.007 · Cited by 48 · see citing works

Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics

Wei, C., Jiang, Z., Li, C., Li, P., & Fu, Q. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202214655 · Cited by 43 · see citing works

Chasing LDL cholesterol to the bottom — PCSK9 in perspective

Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 38 · see citing works

The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis

Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36 · see citing works

Celastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential

Gu, J., Shi, Y., Zhu, N., Li, H., Zhang, C., & Li, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114981 · Cited by 36 · see citing works

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 38 · see citing works

Engineered exosomes as a prospective therapy for diabetic foot ulcers

Guo, L., Xiao, D., Xing, H., Yang, G., & Yang, X. (2024) · Burns & Trauma · doi:10.1093/burnst/tkae023 · Cited by 39 · see citing works

Discordant High Remnant Cholesterol With LDL-C Increases the Risk of Stroke: A Chinese Prospective Cohort Study

Han, M., Huang, K., Shen, C., Hu, H., Liu, F., Li, J., Yang, X., Chen, J.-C., Liu, X., Cao, J., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.046811 · Cited by 35 · see citing works

The potential impact of inflammation on the lipid paradox in patients with acute myocardial infarction: a multicenter study

Zeng, G., Zhang, C., Song, Y., Zhang, Z., Xu, J., Liu, Z., Tang, X., Wang, X., Chen, Y., Zhang, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03823-z · Cited by 35 · see citing works

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans

Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 36 · see citing works

Diagnostic and Therapeutic Aptamers

Mauro, V. D., Lauta, F. C., Modica, J., Appleton, S. L., de Franciscis, V., & Catalucci, D. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.013 · Cited by 32 · see citing works

Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE-/- mice with minimal side effects

Zhang, L. N., Wang, C., Hu, W., Bu, T., Sun, W., Zhou, T., Qiu, S., Wei, M., Xing, H., Li, Z., et al. (2023) · Theranostics · doi:10.7150/thno.87484 · Cited by 32 · see citing works

Remnant cholesterol and low-grade inflammation jointly in atherosclerotic cardiovascular disease: implications for clinical trials

Elías-López, D., Doi, T., Nordestgaard, B. G., & Kobylecki, C. J. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000999 · Cited by 29 · see citing works

MaiJiTong granule attenuates atherosclerosis by reducing ferroptosis via activating STAT6-mediated inhibition of DMT1 and SOCS1/p53 pathways in LDLR−/− mice

Shi, J., Yang, M. M., Yang, S., Fan, F., Zhang, J., Miao, Y., Hua, Y., Zhang, J., Cheng, Y., Liu, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155489 · Cited by 30 · see citing works

New approaches to triglyceride reduction: is there any hope left?

Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26 · see citing works

Hypertriglyceridemia Therapy: Past, Present and Future Perspectives

Canfora, I., & Pierno, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179727 · Cited by 27 · see citing works

Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations

Liu, Y., Lu, K., Zhang, R., Hu, D., Yang, Z., Zeng, J., & Cai, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00574 · Cited by 24 · see citing works

Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery

May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 23 · see citing works

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy

Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Inkeri, J., Hakkarainen, A., Parviainen, H., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06008-0 · Cited by 23 · see citing works

The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications

Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23 · see citing works

Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation

Silbernagel, G., Chen, Y., Rief, M., Kleber, M. E., Hoffmann, M. M., Stojaković, T., Stang, A., Sarzynski, M. A., Bouchard, C., März, W., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad261 · Cited by 22 · see citing works

Ceramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets

Klingenberg, R., Leiherer, A., Dobrev, D., Kaski, J. C., Levkau, B., März, W., Sossalla, S. T., von Eckardstein, A., & Drexel, H. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf093 · Cited by 21 · see citing works

Updates in Small Interfering RNA for the Treatment of Dyslipidemias

Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 21 · see citing works

Precision cardiovascular medicine: shifting the innovation paradigm

Aikawa, M., Sonawane, A. R., Chelvanambi, S., Asano, T., Halu, A., Matamalas, J. T., Singh, S. A., Uchida, S., Aïkawa, E., Arenas, À., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1474469 · Cited by 22 · see citing works

CpG-Conjugated Silver Nanoparticles as a Multifunctional Nanomedicine to Promote Macrophage Efferocytosis and Repolarization for Atherosclerosis Therapy

Tang, C., Wang, H., Guo, L., Zou, C., Hu, J., Zhang, H., Zhou, W., & Yang, G. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11227 · Cited by 20 · see citing works

Gene therapy for polygenic or complex diseases

Wu, T., Hu, Y., & Tang, L. V. (2024) · Biomarker Research · doi:10.1186/s40364-024-00618-5 · Cited by 21 · see citing works

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20 · see citing works

HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype

Luo, F., Cao, J., Chen, Q., Liu, L., Yang, T., Bai, X., Ma, W., Lin, C., Zhou, T., Zhan, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008146 · Cited by 18 · see citing works

Exploring the Molecular Mechanism of Schisandrin C for the Treatment of Atherosclerosis via the PI3K/AKT/mTOR Autophagy Pathway

Duan, H. Q., Li, H., Liu, T., Chen, Y., Luo, M., Shi, Y., Zhou, J., Rashed, M. M. A., Zhai, K., Li, L., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03738 · Cited by 18 · see citing works

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice

Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 17 · see citing works

Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries

Farnier, M., Santos, R. D., Cosı́n-Sales, J., Владиславович, Е. М., Liu, J., Granados, D., Santoni, S., Khan, I., & Catapano, A. L. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac214 · Cited by 17 · see citing works

Opportunities and Challenges for Inhibitors Targeting Citrate Transport and Metabolism in Drug Discovery

Zhang, L., Hu, W., Qiu, Z., Li, Z., & Bian, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00179 · Cited by 17 · see citing works

Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients

Gaiţă, L., Timar, B., Timar, R. Z., Fras, Z., Gaiță, D. I., & Banach, M. (2024) · Pharmaceuticals · doi:10.3390/ph17020219 · Cited by 17 · see citing works

Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?

Adamidis, P. S., Pantazi, D., Moschonas, I. C., Liberopoulos, E. N., & Tselepis, A. D. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11030072 · Cited by 19 · see citing works

Immuno-modulatory role of baicalin in atherosclerosis prevention and treatment: current scenario and future directions

Wang, L., Huang, S., Liang, X., Zhou, J.-L., Han, Y., He, J., & Xu, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377470 · Cited by 17 · see citing works

The calcium-sensing-receptor (CaSR) in adipocytes contributes to sex-differences in the susceptibility to high fat diet induced obesity and atherosclerosis

Adam, S., Maas, S. L., Huchzermeier, R., Rakateli, L., Abschlag, K., Hohl, M., Liao, L., Bartneck, M., Teunissen, M., Wouters, K., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105293 · Cited by 17 · see citing works

Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes

Lee‐Rueckert, M., Jauhiainen, M., Kovanen, P. T., & Escolá‐Gil, J. C. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.008 · Cited by 16 · see citing works

Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?

Doi, T., Nordestgaard, B. G., & Langsted, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000799 · Cited by 17 · see citing works

Yam Gruel alone and in combination with metformin regulates hepatic lipid metabolism disorders in a diabetic rat model by activating the AMPK/ACC/CPT-1 pathway

Dai, Y., Chen, Q., Zhang, D., Li, M., & Liu, W. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02014-2 · Cited by 16 · see citing works

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Arriola, E., de Castro, J., García-Campelo, R., Bernárdez, B., Bernabé, R., Bruna, J., Dómine, M., Isla, D., Juan, Ó., López‐Fernández, T., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01379-7 · Cited by 17 · see citing works

Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks

Qian, X., Sun, J. M., Li, F., Li, X., Hu, X., Dong, N., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690443 · Cited by 15 · see citing works

Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism

Wen, Y., Chen, Y., & Konrad, R. J. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000910 · Cited by 15 · see citing works

Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023

Lee, H., Crawford, E. B., Cho, S. M. J., Krawisz, A. K., Juraschek, S. P., Cluett, J., Lee, H., Kim, H. C., Natarajan, P., Wadhera, R. K., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1607 · Cited by 14 · see citing works

Using a k-means clustering to identify novel phenotypes of acute ischemic stroke and development of its Clinlabomics models

Jiang, Y., Dang, Y., Wu, Q. Y., Yuan, B., Gao, L., & You, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1366307 · Cited by 16 · see citing works

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis

Lin, Y., Lin, R., Lin, H.-B., & Shen, S. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100189 · Cited by 14 · see citing works

Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment

Liu, X., Zhang, K., Yin, M., Bai, Y., Hu, C., Lei, Z., Meng, F., & Luo, L. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.4c00055 · Cited by 14 · see citing works

Metabolic Reprogramming and Cell Interaction in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies

Liu, Y., Guo, F.-M., Qiu, W.-J., Gao, Y.-P., Han, X., & Shen, B. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12100384 · Cited by 12 · see citing works

Celastrus orbiculatus Thunb. extracts and celastrol alleviate NAFLD by preserving mitochondrial function through activating the FGF21/AMPK/PGC-1α pathway

Xue, J., Liu, Y., Liu, B., Jia, X., Fang, X., Qin, S., & Zhang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444117 · Cited by 12 · see citing works

Beneficial Effects of Moderate Hepatic Activin A Expression on Metabolic Pathways, Inflammation, and Atherosclerosis

Liu, H., Hastings, M. H., Kitchen, R. R., Xiao, C., Guerra, J. R. B., Kuznetsov, A., & Rosenzweig, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318138 · Cited by 12 · see citing works

The systemic impact of non‐surgical treatment of peri‐implantitis with or without adjunctive systemic metronidazole: Secondary analysis of a randomized clinical trial

Liñares, A., Dopico, J., Blanco, C., Pico, A., Sobrino, T., Blanco, J., & Leira, Y. (2024) · Clinical Oral Implants Research · doi:10.1111/clr.14339 · Cited by 11 · see citing works

Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review

Alqahtani, M. S., Alzibali, K. F., Mahdi, A. M. M., Alharbi, O. M. A., Harbi, R. H. A., Alkhaldi, H. S. M., Alsayafi, Z. A. A., Bisher, F. H. A., Buqurayn, M. H., & Alharbi, M. M. (2024) · Cureus · doi:10.7759/cureus.65202 · Cited by 11 · see citing works

Stilbene glycosides alleviate atherosclerosis partly by promoting lipophagy of dendritic cells

Yang, Y., Bai, D., Jiang, L., Chen, Y., Wang, M., Wang, W., Wang, H., He, Q., Bu, G., Long, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113223 · Cited by 12 · see citing works

Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression

Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 10 · see citing works

Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?

Surma, S., Sahebkar, A., & Banach, M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01186-z · Cited by 10 · see citing works

Engineering molecular nanoprobes to target early atherosclerosis: Precise diagnostic tools and promising therapeutic carriers

Zan, C., An, J., Wu, Z., & Li, S. (2023) · Nanotheranostics · doi:10.7150/ntno.82654 · Cited by 10 · see citing works

An update on inclisiran for the treatment of elevated LDL cholesterol

Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9 · see citing works

Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?

Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad241 · Cited by 9 · see citing works

WTAP Promotes Atherosclerosis by Inducing Macrophage Pyroptosis and M1 Polarization through Upregulating NLRP3

Luo, X., He, C., Yang, B., Yin, S., & Li, L. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05106-y · Cited by 8 · see citing works

Qingre Sanjie Formula alleviates atherosclerosis by promoting LXR-α/ABCG5/G8-mediated reverse cholesterol transport and bile acid synthesis

Li, X., Huang, X., Song, K., Liu, J., Jin, Y., Li, T., Zhang, L., & Zhang, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156691 · Cited by 8 · see citing works

Significance of Residual Inflammatory Risk and Persistent Inflammation in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries

Gao, S., Huang, S., Liu, X., Yu, M., & Li, W. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s547594 · Cited by 8 · see citing works

Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action

Crea, F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac479 · Cited by 8 · see citing works

A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3

Xiao, Q., Wang, L., Wang, J., Wang, M., Wang, D. W., & Ding, H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102011 · Cited by 7 · see citing works

Reprogramming and targeting of cholesterol metabolism in tumor-associated macrophages

Ma, Q., Zhu, Y., Zhang, D., Su, X., Jiang, C., Zhang, Y., Zhang, X., Han, N., Shu, G., Yin, G., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00236b · Cited by 7 · see citing works

Microenvironments‐Targeted Nanomaterials for Atherosclerosis Therapy

Song, C., Ling, H., Yang, G., & Ding, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202421512 · Cited by 7 · see citing works

Remnant cholesterol, high-sensitivity C-reactive protein, and risk of incident coronary heart disease among patients with chronic kidney disease based on UK biobank

Han, M., Zhou, J., Wan, Z., Chen, M., Yan, M., Feng, W. S., Wang, G., Zhang, J., Zhang, L., Yan, L., et al. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00982-5 · Cited by 8 · see citing works

Lp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study

Fernández-Olmo, M. R., Bailén, M. C., Quesada, M. M., Mansilla, C. R., Toro, M. M., Suárez, A. L., García, M. L., Quiroga, G. A. C., Bernal, B. C., Cruces, S. O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082256 · Cited by 7 · see citing works

Therapies leading to coronary atherosclerosis plaque regression: a scientific statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy Part 1: Atherosclerosis Pathophysiology and Imaging Evaluation

Conte, E., Perone, F., Cosyns, B., Dweck, M. R., Donal, E., Gonçalves, I., Ibáñez, B., Kaski, J. C., Maurovich‐Horvat, P., Onuma, Y., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf594 · Cited by 6 · see citing works

Targeting KEAP1/NRF2 interaction with oleuropein ameliorates atherosclerosis by inhibiting macrophage ferroptosis

Zhu, X., Chen, Y., Xu, B., Mou, J., Wang, M., Gu, Q., Sun, Q., Li, M., Zhao, C., Zeng, M. Y., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.036 · Cited by 6 · see citing works

P2Y6 receptor: A promising therapeutic target for atherosclerosis

Li, L., Lai, L., Qiu, D., Ding, Y., Yu, M., Zhang, T., Wang, Z., & Wang, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177513 · Cited by 5 · see citing works

Traditional medicine Kuanxiong Aerosol alleviates atherosclerotic plaque inflammation by mitigating CX3CR1+ macrophage apoptosis via the cGAS–STING pathway

Chen, Y., Wang, G., Jiang, Y., Qian, K., Liu, Y., Qiu, C., & Huang, P. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157120 · Cited by 5 · see citing works

Early Supplementation with Branched-Chain Amino Acids Ameliorates Lipid Retention in Aortic Valves of ApoE-Knockout Mice

Shishkova, D. K., Kanonykina, A., Андреевич, К. Е., Евгеньевна, Т. А., Morozova, A., Poddubnyak, A., Sinitskaya, А. V., Sinitsky, M. Y., Markova, V. E., Lazebnaya, A. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311259 · Cited by 5 · see citing works

Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics

Schmidt, L. E., Speidl, W. S., Tsimikas, S., & Mayr, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad294 · Cited by 5 · see citing works

Exploring global research trends in Chinese medicine for atherosclerosis: a bibliometric study 2012–2023

Tan, M., Wang, J., Chen, Z., & Xie, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1400130 · Cited by 5 · see citing works

Exploring the relationship between NHHR and the degree of coronary artery stenosis in patients with acute coronary syndromes

Yang, Z., Li, Y.-J., Yang, M., Xu, Y. X. Z., Yao, J., Wang, K., & Gao, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05066-z · Cited by 5 · see citing works

Heterozygosity for ADP-ribosylation factor 6 suppresses the burden and severity of atherosclerosis

Gogulamudi, V., Islam, M. T., Durrant, J., Adeyemo, A. O., Trott, D. W., Hyuhn, M. H., Zhu, W.-Q., Donato, A. J., Walker, A. E., & Lesniewski, L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285253 · Cited by 8 · see citing works

Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors—design and rationale of the Stockholm hyperTRIglyceridaemia REGister study

Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4 · see citing works

Atherosclerosis prediction: three pathways, stronger insights

Rocha, V. Z. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf396 · Cited by 4 · see citing works

Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis

Li, C., Chen, Y., Li, Y., Liu, H., Yang, S., Lin, Y., Qi, Y., Han, S., Dou, Y., Luo, G., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.039 · Cited by 4 · see citing works

Targeting hypercholesterolaemia: challenges and opportunities

Crea, F. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad415 · Cited by 4 · see citing works

Genetic causal association between lipidomic profiles, inflammatory proteomics, and aortic stenosis: a Mendelian randomization investigation

Zhu, L., Li, N., Shi, H., Shao, G., & Sun, L. (2024) · European journal of medical research · doi:10.1186/s40001-024-02014-z · Cited by 4 · see citing works

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Liu, D., Zhang, J., Zhang, X., Jiang, F., Wu, Y., Yang, B., Li, X., Fan, X., Han, L., Sun, Y., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1454918 · Cited by 4 · see citing works

Insights Into Causal Effects of Genetically Proxied Lipids and Lipid‐Modifying Drug Targets on Cardiometabolic Diseases

Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4 · see citing works

Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA

Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4 · see citing works

The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis

LYu, P., Pan, H., Hu, K., Xue, Y., Li, Q., Lin, R., Zheng, S., Guo, Z., & Guo, K. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117554 · Cited by 4 · see citing works

Factors associated with lipid lowering therapy in the multi-ethnic study of atherosclerosis

Cao, J., Guan, W., Nomura, S. J. O., Bhatia, H. S., Garg, P. K., & Tsai, M. Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02363-y · Cited by 3 · see citing works

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 3 · see citing works

Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action

Crea, F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac479 · Cited by 8 · see citing works

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3

Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23 · see citing works

A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction

Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3 · see citing works

Lower, Earlier, Longer and Personalized: Rethinking Lipid‐Lowering Therapy for Cardiovascular Prevention

Valle, C. D., Zuin, M., & Bilato, C. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70267

Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges

Lalic, K. S., Rajkovic, N., Popović, L., Lukač, S. S., Rasulić, I., Petakov, A., Krstic, M., & Mitrović, M. (2024) · Galenika Medical Journal · doi:10.5937/galmed2409031l · Cited by 2 · see citing works